vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and TREX CO INC (TREX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $343.4M, roughly 1.8× TREX CO INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 17.9%, a 16.6% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 1.0%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -4.5%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Trex Company, Inc. is a manufacturer of wood-alternative composite decking, residential railing, and other outdoor items made from recycled materials. Its headquarters is in Winchester, Virginia.
RPRX vs TREX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $343.4M |
| Net Profit | $214.2M | $61.4M |
| Gross Margin | — | 40.5% |
| Operating Margin | 62.4% | 24.3% |
| Net Margin | 34.4% | 17.9% |
| Revenue YoY | 4.8% | 1.0% |
| Net Profit YoY | 2.9% | 1.6% |
| EPS (diluted) | $0.49 | $0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $343.4M | ||
| Q4 25 | $622.0M | $161.1M | ||
| Q3 25 | $609.3M | $285.3M | ||
| Q2 25 | $578.7M | $387.8M | ||
| Q1 25 | $568.2M | $340.0M | ||
| Q4 24 | $593.6M | $167.6M | ||
| Q3 24 | $564.7M | $233.7M | ||
| Q2 24 | $537.3M | $376.5M |
| Q1 26 | — | $61.4M | ||
| Q4 25 | $214.2M | $2.3M | ||
| Q3 25 | $288.2M | $51.8M | ||
| Q2 25 | $30.2M | $75.9M | ||
| Q1 25 | $238.3M | $60.4M | ||
| Q4 24 | $208.2M | $9.8M | ||
| Q3 24 | $544.0M | $40.6M | ||
| Q2 24 | $102.0M | $87.0M |
| Q1 26 | — | 40.5% | ||
| Q4 25 | — | 30.2% | ||
| Q3 25 | — | 40.5% | ||
| Q2 25 | — | 40.8% | ||
| Q1 25 | — | 40.5% | ||
| Q4 24 | — | 32.7% | ||
| Q3 24 | — | 39.9% | ||
| Q2 24 | — | 44.7% |
| Q1 26 | — | 24.3% | ||
| Q4 25 | 62.4% | 2.2% | ||
| Q3 25 | 70.1% | 24.7% | ||
| Q2 25 | 36.3% | 26.4% | ||
| Q1 25 | 94.0% | 24.0% | ||
| Q4 24 | 60.9% | 9.2% | ||
| Q3 24 | — | 23.2% | ||
| Q2 24 | 50.2% | 31.1% |
| Q1 26 | — | 17.9% | ||
| Q4 25 | 34.4% | 1.4% | ||
| Q3 25 | 47.3% | 18.1% | ||
| Q2 25 | 5.2% | 19.6% | ||
| Q1 25 | 41.9% | 17.8% | ||
| Q4 24 | 35.1% | 5.8% | ||
| Q3 24 | 96.3% | 17.4% | ||
| Q2 24 | 19.0% | 23.1% |
| Q1 26 | — | $0.58 | ||
| Q4 25 | $0.49 | $0.03 | ||
| Q3 25 | $0.67 | $0.48 | ||
| Q2 25 | $0.07 | $0.71 | ||
| Q1 25 | $0.55 | $0.56 | ||
| Q4 24 | $0.46 | $0.10 | ||
| Q3 24 | $1.21 | $0.37 | ||
| Q2 24 | $0.23 | $0.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $4.5M |
| Total DebtLower is stronger | $9.0B | — |
| Stockholders' EquityBook value | $9.7B | $995.8M |
| Total Assets | $19.6B | $1.7B |
| Debt / EquityLower = less leverage | 0.92× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $4.5M | ||
| Q4 25 | $618.7M | $3.8M | ||
| Q3 25 | $938.9M | $11.4M | ||
| Q2 25 | $631.9M | $5.5M | ||
| Q1 25 | $1.1B | $5.0M | ||
| Q4 24 | $929.0M | $1.3M | ||
| Q3 24 | $950.1M | $12.8M | ||
| Q2 24 | $1.8B | $1.2M |
| Q1 26 | — | — | ||
| Q4 25 | $9.0B | — | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.6B | — | ||
| Q3 24 | $7.6B | — | ||
| Q2 24 | $7.6B | — |
| Q1 26 | — | $995.8M | ||
| Q4 25 | $9.7B | $1.0B | ||
| Q3 25 | $9.6B | $1.0B | ||
| Q2 25 | $9.5B | $989.3M | ||
| Q1 25 | $9.8B | $910.1M | ||
| Q4 24 | $10.3B | $850.1M | ||
| Q3 24 | $10.3B | $887.9M | ||
| Q2 24 | $9.8B | $894.9M |
| Q1 26 | — | $1.7B | ||
| Q4 25 | $19.6B | $1.5B | ||
| Q3 25 | $19.3B | $1.5B | ||
| Q2 25 | $18.3B | $1.5B | ||
| Q1 25 | $17.6B | $1.6B | ||
| Q4 24 | $18.2B | $1.3B | ||
| Q3 24 | $18.0B | $1.3B | ||
| Q2 24 | $17.7B | $1.3B |
| Q1 26 | — | — | ||
| Q4 25 | 0.92× | — | ||
| Q3 25 | 0.93× | — | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.78× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $-118.4M |
| Free Cash FlowOCF − Capex | — | $-143.4M |
| FCF MarginFCF / Revenue | — | -41.8% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.86× | -1.93× |
| TTM Free Cash FlowTrailing 4 quarters | — | $224.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-118.4M | ||
| Q4 25 | $827.1M | $65.5M | ||
| Q3 25 | $702.6M | $196.9M | ||
| Q2 25 | $364.0M | $249.8M | ||
| Q1 25 | $596.1M | $-154.0M | ||
| Q4 24 | $742.5M | $-8.5M | ||
| Q3 24 | $703.6M | $132.8M | ||
| Q2 24 | $658.2M | $193.7M |
| Q1 26 | — | $-143.4M | ||
| Q4 25 | — | $22.1M | ||
| Q3 25 | — | $142.9M | ||
| Q2 25 | — | $203.0M | ||
| Q1 25 | — | $-233.5M | ||
| Q4 24 | — | $-89.3M | ||
| Q3 24 | — | $54.5M | ||
| Q2 24 | — | $158.2M |
| Q1 26 | — | -41.8% | ||
| Q4 25 | — | 13.7% | ||
| Q3 25 | — | 50.1% | ||
| Q2 25 | — | 52.3% | ||
| Q1 25 | — | -68.7% | ||
| Q4 24 | — | -53.3% | ||
| Q3 24 | — | 23.3% | ||
| Q2 24 | — | 42.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 26.9% | ||
| Q3 25 | — | 18.9% | ||
| Q2 25 | — | 12.1% | ||
| Q1 25 | — | 23.4% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 9.4% |
| Q1 26 | — | -1.93× | ||
| Q4 25 | 3.86× | 28.45× | ||
| Q3 25 | 2.44× | 3.80× | ||
| Q2 25 | 12.06× | 3.29× | ||
| Q1 25 | 2.50× | -2.55× | ||
| Q4 24 | 3.57× | -0.87× | ||
| Q3 24 | 1.29× | 3.27× | ||
| Q2 24 | 6.45× | 2.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
TREX
Segment breakdown not available.
